5paisa Research Team Last Updated: 11th December 2024 - 03:22 pm
5paisa Research Team Last Updated: 11th December 2024 - 03:22 pm
Sai Life Sciences Limited's initial public offering (IPO) has received modest investor interest on its opening day. The IPO witnessed measured participation across categories, with subscription rates reaching 0.05 times by 12:21 PM on December 11, 2024.
The Sai Life Sciences IPO, which opened on December 11, 2024, has seen varied participation across categories. The Retail Investors segment has shown initial interest reaching 0.09 times subscription, while Non-Institutional Investors demonstrated modest participation at 0.04 times. The QIB portion is currently at 0.00 times subscription.
This initial response comes as the company seeks to raise funds in the pharmaceutical research and development sector.
i Don’t Miss Omobiwiut on the Next Big IPO – Invest With Just a Few Clicks!
| Date | QIB | NII | Retail | Total |
| Day 1 (Dec 11)* | 0.00 | 0.04 | 0.09 | 0.05 |
*As of 12:21 PM
Here are the subscription details for Sai Life Sciences IPO as of Day 1 (11th December 2024, 12:21 PM):
| Investor Category | Subscription (times) | Shares Offered | Shares bid for | Total Amount (Rs Cr.) |
| Anchor Investors | 1.00 | 1,66,26,336 | 1,66,26,336 | 912.786 |
| Qualified Institutions | 0.00 | 1,10,84,225 | 2,214 | 0.122 |
| Non-Institutional Buyers | 0.04 | 83,13,168 | 3,71,493 | 20.395 |
| - bNII (>₹10L) | 0.04 | 55,42,113 | 2,24,694 | 12.336 |
| - sNII (<₹10L) | 0.05 | 27,71,056 | 1,46,799 | 8.059 |
| Retail Investors | 0.09 | 1,93,97,392 | 17,27,622 | 94.846 |
| Total | 0.05 | 3,87,94,785 | 21,01,329 | 115.363 |
Total Applications: 52,433
Incorporated in January 1999, Sai Life Sciences Limited has established itself as a leading research and development company specializing in small-molecule new chemical entities. The company has built a strong reputation through its comprehensive range of services to biotech firms and global pharmaceutical companies, serving over 280 innovator pharmaceutical companies in FY2024.
Operating globally, the company's portfolio encompasses various services including contract research, development, and manufacturing organizations (CRDMO). They work with 18 of the top 25 pharmaceutical companies across countries such as the US, UK, Europe, and Japan. With 2,353 scientific staff, including 302 Ph.D.s and 1,475 master's degrees as of September 2024, the company demonstrates strong research capabilities.